Glioblastoma....that's one tough indication to go after, imo. But im glad someone is trying to tackle that one. Apparently, there were 3 deaths, but 2 unrelated to the study from news articles that ive read. And that begs the question as to just how fragile are the patients being treated??? I would think that any death would send the researchers scrambling to determine cause and correlation to previous clinical results/models....but with respect to glioblastoma, can they do so with absolute certainty?? With patients in such fragile states, i wonder?? So, another question i have is just how much headroom (ie, health) does the CAR-T treatment require from anyone afflicted? Does it push those on the edge over the edge before it has a chance to be effective??....note that it is my understanding that it wasnt very long after treatment that the unfortunate occurred with that one individual in the study. One thing seems rather obvious, that the bar to hurdle over is much higher than it was in the weeks prior to that announcement. However, considering the fragile state of those enrolled in the study, perhaps the researchers already knew of the difficulty...the height of the hurdle that was made obvious of late. But again, someone had to try this unique immunotherapy against this particularly terrible disease. I hope ZIOP is successful, but their challenges are many.
Just my opinion.
News 
Market Data 
Discover 
AI
